Skip to main content
SpringerLink
Log in

The Economic Value of a New Insulin Preparation, Humalog® Mix 25™

Measured by a Willingness-To-Pay Approach

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective:To measure the economic value of a new insulin formulation consisting of rapid-acting insulin lispro and intermediate-acting neutral protamine lispro in a 25: 75 ratio (Humalog® Mix 25™).

Design and Setting: A cost-benefit analysis using a consumer-based willingness-to- pay (WTP) approach was used. The study sample consisted of 80 Canadian taxpayers randomly selected from Ontario and Quebec. After background information on the differences between Humalog® Mix 25™ and human 30/70 insulin were presented, respondents were asked what their preferred product would be if they were diagnosed with diabetes mellitus. Respondents were then asked the maximum premium that they would pay per month in the form of a user’s fee for the insulin of their choice.

Study Perspective: Canadian taxpayer perspective.

Main Outcome Measures and Results: The WTP survey instrument was simple to administer and easily understood by participants. Approximately 84% of the sample of taxpayers preferred to use Humalog® Mix 25™ rather than human 30/70 insulin and were willing to pay for it (p = 0.012). They were willing to pay a mean of $Can35.28 [95% confidence interval (CI): $Can27.50 to $Can43.07] per month for the benefits offered by Humalog® Mix 25™, which was at least 2-fold higher than the incremental monthly cost of the drug (1999 values).

Conclusions: The results of the study revealed that Canadians prefer to use Humalog® Mix 25™ instead of human 30/70 insulin, and they would be willing to pay for it. Compared with other drugs, this overall net gain suggests that Humalog® Mix 25™ represents good value for money and should be considered for reimbursement by government formularies and other third-party payers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1

Similar content being viewed by others

References

  1. Tan H, MacLean DR. Epidemiology of diabetes in Canada. Clin Invest Med 1995; 18: 240–6

    PubMed  CAS  Google Scholar 

  2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 Suppl. 5: S1–85

    Article  Google Scholar 

  3. Jonsson B. The economic impact of diabetes. Diabetes Care 1998; 21 Suppl. 3: C7–10

    Google Scholar 

  4. The Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

    Article  Google Scholar 

  5. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17

    Article  PubMed  CAS  Google Scholar 

  6. Howey DC, Bowsher RR, Brunelle R, et al. (Lys[B28], Pro[B29])- human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396–402

    Article  PubMed  CAS  Google Scholar 

  7. Pfutzner A, Kustner E, Forst T, et al. Intensive insulin therapy with insulin Humalog in patients with type I diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996; 104: 25–30

    Article  PubMed  CAS  Google Scholar 

  8. Anderson JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997; 46: 265–70

    Article  PubMed  CAS  Google Scholar 

  9. Davey P, Grainger DL, MacMillan J, et al. Clinical outcomes with insulin Humalog compared with regular insulin: a meta analysis. Clin Ther 1997; 19: 656–74

    Article  PubMed  CAS  Google Scholar 

  10. Ebeling P, Jansson P, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care 1997; 20: 1287–9

    Article  PubMed  CAS  Google Scholar 

  11. Jansson P, Ebeling P, Smith U, et al. Glycemic control in IDDM is improved by optimized combination of insulin lispro and basal insulin [abstract]. Diabetes 1997; 46 Suppl. 1: 162A

    Google Scholar 

  12. Koivisto VA, Tuominen JA, Ebeling P, et al. Humalog Mix 25 insulin as premeal therapy in type II diabetic patients. Diabetes Care 1999; 22: 459–62

    Article  PubMed  CAS  Google Scholar 

  13. Malone JK, Woodworth JR, Arora V, et al. Improved postprandial glycemic control with Humalog Mix 75/25 after a standard test meal in patients with type 2 diabetes. Clin Ther 2000; 22: 222–30

    Article  PubMed  CAS  Google Scholar 

  14. Lalli C, Ciofetta M, Del Sindaco P, et al. Long term intensive treatment of type 1 diabetics with the short acting insulin analog Humalog in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468–77

    Article  PubMed  CAS  Google Scholar 

  15. O’Brien B, Gafni A. When do the ‘dollars’ make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996; 16: 288–99

    Article  PubMed  Google Scholar 

  16. Gafni A. Using willingness-to-pay as a measure of benefits: what is the relevant question to ask in the context of public decision making about health care problems? Med Care 1991; 29: 1246–52

    Article  PubMed  CAS  Google Scholar 

  17. Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin Humalog-protamine formulations, Insulin Humalog Mix 25 and Insulin Humalog Mix 50. Clin Ther 1999; 21: 523–34

    Article  PubMed  CAS  Google Scholar 

  18. Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9: 535–59

    Article  PubMed  CAS  Google Scholar 

  19. Meltzer S, Leiter L, Daneman D, et al. Clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998; 159 Suppl. 8: S1–29

    Google Scholar 

  20. Mitchell RC, Carson RT. A contingent valuation estimate of national freshwater benefits: technical report to the U.S. environmental protection agency. Washington, DC: Resources for the Future, 1984

    Google Scholar 

  21. Davey P, Grainger D, MacMillan J, et al. Economic evaluation of insulin Humalog versus neutral insulin therapy using a willingness to pay approach. Pharmacoeconomics 1998; 13: 347–58

    Article  PubMed  CAS  Google Scholar 

  22. George SL. Identification and assessment of prognostic factors. Semin Oncol 1988; 15: 462–71

    PubMed  CAS  Google Scholar 

  23. Feinstein AR. Multivariate analysis: an introduction. New Haven (CT): Yale University Press, 1996

    Google Scholar 

  24. Cresswell JW. Qualitative inquiry and research design: choosing among five traditions. Thousand Oaks (CA): Sage, 1998

    Google Scholar 

  25. Ortega A, Dranitsaris G, Puodziunas A. What are cancer patients willing to pay for epoetin alfa: a cost-benefit analysis. Cancer 1998; 83: 2588–96

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by Eli Lilly Canada Inc.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Services, The University Health Network/Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada

    George Dranitsaris

  2. Eli Lilly Canada Inc., Toronto, Ontario, Canada

    Christopher J. Longo & Loren D. Grossman

Authors
  1. George Dranitsaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Longo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Loren D. Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Dranitsaris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dranitsaris, G., Longo, C.J. & Grossman, L.D. The Economic Value of a New Insulin Preparation, Humalog® Mix 25™. Pharmacoeconomics 18, 275–287 (2000). https://doi.org/10.2165/00019053-200018030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200018030-00007

Keywords

Search

Navigation